PCSK9 inhibitors for in-hospital treatment of patients with acute coronary syndrome and severe lipid metabolism disorders

PCSK9 inhibitors for in-hospital treatment of patients with acute coronary syndrome and severe lipid metabolism disorders

Aim. To assess the efficacy and safety of PCSK9 inhibitor alirocumab as part of a combination lipid-lowering therapy in patients with acute coronary syndrome (ACS).Material and methods. This prospective, open-label, single-center activetreatment study included 13 patients hospitalized due to ACS. Th...

Full description

Saved in:
Bibliographic Details
Main Authors: O. L. Barbarash, N. V. Fedorova, D. Yu. Sedykh, O. V. Gruzdeva, O. N. Khryachkova, V. V. Kashtalap, A. A. Filimonova
Format: Article
Language:Russian
Published: «FIRMA «SILICEA» LLC 2020-09-01
Series:Российский кардиологический журнал
Subjects:
dyslipidemia
acute coronary syndrome
pcsk9 inhibitors
alirocumab
Online Access:https://russjcardiol.elpub.ru/jour/article/view/4010
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items